Mark JD - Mind Medicine Chief Secretary
| MNMD Stock | USD 7.40 0.24 3.35% |
Executive
Mark JD is Chief Secretary of Mind Medicine
| Age | 53 |
| Address | One World Trade Center, New York, NY, United States, 10007 |
| Phone | 212-220-6633 |
| Web | https://www.mindmed.co |
Mind Medicine Management Efficiency
The company has return on total asset (ROA) of (0.2538) % which means that it has lost $0.2538 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5461) %, meaning that it created substantial loss on money invested by shareholders. Mind Medicine's management efficiency ratios could be used to measure how well Mind Medicine manages its routine affairs as well as how well it operates its assets and liabilities. As of December 16, 2024, Return On Tangible Assets is expected to decline to -0.97. In addition to that, Return On Capital Employed is expected to decline to -1.07. At present, Mind Medicine's Tangible Asset Value is projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.11, whereas Net Tangible Assets are forecasted to decline to about 91.5 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Brian MBA | Iovance Biotherapeutics | N/A | |
| Abha Bommireddi | Protagonist Therapeutics | N/A | |
| Kevin Smyth | Iovance Biotherapeutics | N/A | |
| Mohammad Masjedizadeh | Protagonist Therapeutics | N/A | |
| Matthew JD | Protagonist Therapeutics | 53 | |
| Kimberly Freeman | Zentalis Pharmaceuticals Llc | N/A | |
| FACP MD | Protagonist Therapeutics | 65 | |
| Adrian MD | Zentalis Pharmaceuticals Llc | N/A | |
| Tracy Winton | Iovance Biotherapeutics | N/A | |
| Joseph MD | Syndax Pharmaceuticals | N/A | |
| PharmD Rasbach | Zentalis Pharmaceuticals Llc | 44 | |
| David Liu | Protagonist Therapeutics | 74 | |
| Hequn Yin | Iovance Biotherapeutics | 59 | |
| Richard Shames | Protagonist Therapeutics | 64 | |
| Sara Pellegrino | Iovance Biotherapeutics | N/A | |
| Ingmar MD | Zentalis Pharmaceuticals Llc | 49 | |
| Catherine MD | Syndax Pharmaceuticals | 52 | |
| Scott MD | Protagonist Therapeutics | N/A | |
| Steven Closter | Syndax Pharmaceuticals | N/A | |
| James MBA | Iovance Biotherapeutics | N/A | |
| Sharon Klahre | Syndax Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.25 |
Mind Medicine Leadership Team
Elected by the shareholders, the Mind Medicine's board of directors comprises two types of representatives: Mind Medicine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mind. The board's role is to monitor Mind Medicine's management team and ensure that shareholders' interests are well served. Mind Medicine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mind Medicine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MA, Chief Officer | ||
| Schond MBA, Chief Officer | ||
| Miriam Wernli, Executive President | ||
| Maxim CFA, Vice Communications | ||
| Wong JD, Chief Sec | ||
| Gregg Pratt, Chief Officer | ||
| MD MBA, Chief Officer | ||
| Mark JD, Chief Secretary | ||
| Scott MD, CoFounder Advisor | ||
| BA MA, Executive President | ||
| Stephanie Fagan, Chief Officer | ||
| Leonard Latchman, Cofounder | ||
| Schond Greenway, Chief Officer | ||
| CGMA CPA, VP Officer | ||
| Robert Barrow, CEO Director |
Mind Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mind Medicine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 271.68 M | ||||
| Shares Outstanding | 73.33 M | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 68.09 % | ||||
| Number Of Shares Shorted | 9.71 M | ||||
| Price To Book | 2.07 X | ||||
| EBITDA | (92.57 M) | ||||
| Net Income | (95.73 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Mind Medicine is a strong investment it is important to analyze Mind Medicine's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mind Medicine's future performance. For an informed investment choice regarding Mind Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mind Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Mind Stock refer to our How to Trade Mind Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mind Medicine. If investors know Mind will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mind Medicine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Return On Assets (0.25) | Return On Equity (0.55) |
The market value of Mind Medicine is measured differently than its book value, which is the value of Mind that is recorded on the company's balance sheet. Investors also form their own opinion of Mind Medicine's value that differs from its market value or its book value, called intrinsic value, which is Mind Medicine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mind Medicine's market value can be influenced by many factors that don't directly affect Mind Medicine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mind Medicine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mind Medicine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mind Medicine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.